🚀 VC round data is live in beta, check it out!
Guardant Health Valuation Multiples
Discover revenue and EBITDA valuation multiples for Guardant Health and similar public comparables like Pro Medicus, bioMérieux, Revvity, United Imaging and more.
Guardant Health Overview
About Guardant Health
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Founded
2011
HQ
Employees
2.5K
Website
Financials (LTM)
EV
$12B
Guardant Health Financials
Guardant Health reported last 12-month revenue of $1B and negative EBITDA of ($209M).
In the same LTM period, Guardant Health generated $691M in gross profit, ($209M) in EBITDA losses, and had net loss of ($402M).
Revenue (LTM)
Guardant Health P&L
In the most recent fiscal year, Guardant Health reported revenue of $982M and EBITDA of ($222M).
Guardant Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $982M | XXX | XXX | XXX |
| Gross Profit | $691M | XXX | $633M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | ($209M) | XXX | ($222M) | XXX | XXX | XXX |
| EBITDA Margin | (20%) | XXX | (23%) | XXX | XXX | XXX |
| EBIT Margin | (23%) | XXX | (26%) | XXX | XXX | XXX |
| Net Profit | ($402M) | XXX | ($416M) | XXX | XXX | XXX |
| Net Margin | (38%) | XXX | (42%) | XXX | XXX | XXX |
| Net Debt | — | — | $1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Guardant Health Stock Performance
Guardant Health has current market cap of $12B, and enterprise value of $12B.
Market Cap Evolution
Guardant Health's stock price is $90.35.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12B | $12B | 5.4% | XXX | XXX | XXX | $-3.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGuardant Health Valuation Multiples
Guardant Health trades at 11.6x EV/Revenue multiple, and (59.1x) EV/EBITDA.
EV / Revenue (LTM)
Guardant Health Financial Valuation Multiples
As of April 18, 2026, Guardant Health has market cap of $12B and EV of $12B.
Equity research analysts estimate Guardant Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Guardant Health has a P/E ratio of (29.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12B | XXX | $12B | XXX | XXX | XXX |
| EV (current) | $12B | XXX | $12B | XXX | XXX | XXX |
| EV/Revenue | 11.6x | XXX | 12.6x | XXX | XXX | XXX |
| EV/EBITDA | (59.1x) | XXX | (55.7x) | XXX | XXX | XXX |
| EV/EBIT | (49.7x) | XXX | (47.7x) | XXX | XXX | XXX |
| EV/Gross Profit | 17.9x | XXX | 19.5x | XXX | XXX | XXX |
| P/E | (29.5x) | XXX | (28.5x) | XXX | XXX | XXX |
| EV/FCF | (51.5x) | XXX | (53.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Guardant Health Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Guardant Health Margins & Growth Rates
Guardant Health's revenue in the last 12 month grew by 29%.
Guardant Health's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Guardant Health's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Guardant Health's rule of X is 60% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Guardant Health Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Margin | (20%) | XXX | (23%) | XXX | XXX | XXX |
| EBITDA Growth | (34%) | XXX | (20%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 47% | XXX | 50% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 17% | XXX | 22% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 32% | XXX | 37% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 109% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Guardant Health Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics and Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Guardant Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Pro Medicus | XXX | XXX | XXX | XXX | XXX | XXX |
| bioMérieux | XXX | XXX | XXX | XXX | XXX | XXX |
| Revvity | XXX | XXX | XXX | XXX | XXX | XXX |
| United Imaging | XXX | XXX | XXX | XXX | XXX | XXX |
| Qiagen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guardant Health M&A Activity
Guardant Health acquired XXX companies to date.
Last acquisition by Guardant Health was on XXXXXXXX, XXXXX. Guardant Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Guardant Health
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGuardant Health Investment Activity
Guardant Health invested in XXX companies to date.
Guardant Health made its latest investment on XXXXXXXX, XXXXX. Guardant Health invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Guardant Health
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Guardant Health
| When was Guardant Health founded? | Guardant Health was founded in 2011. |
| Where is Guardant Health headquartered? | Guardant Health is headquartered in United States. |
| How many employees does Guardant Health have? | As of today, Guardant Health has over 2K employees. |
| Who is the CEO of Guardant Health? | Guardant Health's CEO is Helmy Eltoukhy. |
| Is Guardant Health publicly listed? | Yes, Guardant Health is a public company listed on Nasdaq. |
| What is the stock symbol of Guardant Health? | Guardant Health trades under GH ticker. |
| When did Guardant Health go public? | Guardant Health went public in 2018. |
| Who are competitors of Guardant Health? | Guardant Health main competitors are Pro Medicus, bioMérieux, Revvity, United Imaging. |
| What is the current market cap of Guardant Health? | Guardant Health's current market cap is $12B. |
| What is the current revenue of Guardant Health? | Guardant Health's last 12 months revenue is $1B. |
| What is the current revenue growth of Guardant Health? | Guardant Health revenue growth (NTM/LTM) is 29%. |
| What is the current EV/Revenue multiple of Guardant Health? | Current revenue multiple of Guardant Health is 11.6x. |
| Is Guardant Health profitable? | No, Guardant Health is not profitable. |
| What is the current EBITDA of Guardant Health? | Guardant Health has negative EBITDA and is not profitable. |
| What is Guardant Health's EBITDA margin? | Guardant Health's last 12 months EBITDA margin is (20%). |
| What is the current EV/EBITDA multiple of Guardant Health? | Current EBITDA multiple of Guardant Health is (59.1x). |
| What is the current FCF of Guardant Health? | Guardant Health's last 12 months FCF is ($240M). |
| What is Guardant Health's FCF margin? | Guardant Health's last 12 months FCF margin is (22%). |
| What is the current EV/FCF multiple of Guardant Health? | Current FCF multiple of Guardant Health is (51.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.